ArticleLung Cancer (Auckland, N.Z.)2023

Stage as the Sole "Biomarker" for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091?

Misako Nagasaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.